One in two Europeans believe biotechnology will improve quality of life

52% of those polled in the latest Eurobarometer survey on biotechnology, published today, indicated a belief that biotechnology will improve their quality of life. The Eurobarometer "Europeans and biotechnology in 2005" shows that most Europeans are in favour of medical (red) applications of biotechnology when there are clear benefits for human health; and industrial (white) applications, but they are still mostly sceptical about agricultural (green) biotech, and will continue to be so unless new crops and products are seen to have consumer benefits. Confidence has increased in the European Union's regulation of biotechnology but there is no evidence that this has influenced the public's reported purchasing intentions, especially for GM foods. Overall, optimism about biotechnology's contribution to improving society has grown significantly since 1999. There is also support for research using stem cells, provided this is tightly regulated. This survey is the latest in a series of regular surveys on attitudes to biotechnology undertaken since 1991.

The survey examines issues such as:

  • Optimism about the contribution of technology , including biotechnology, to our way of life. Here, the survey shows that optimism about biotechnology has increased since 1999, after a period of decline (52% say it will improve their life).
  • The development of nanotechnology, pharmacogenetics (analysing a person’s genetic code in order to create drugs which are tailored to him/her and are therefore more effective) and gene therapy, all three of which are generally perceived as useful to society and morally acceptable.
  • GM food , where a majority of Europeans (58%) think it should not be encouraged.
  • Industrial (white) biotechnologies, such as bio-fuels, bio-plastics (plastics manufactures from crop plants) and biopharming (the use of genetically modified plants in the production of medicines and pharmaceutical products) for pharmaceuticals, which are widely supported.
  • Stem cell research , where there is considerable support across Europe, if tightly regulated. There is approval for use of both stem cells derived from umbilical cords (65%) and embryonic stem cells (59%), with 26% of people saying they do not approve of embryonic stem cell research at all or only under very special circumstances.
  • Use of personal genetic data , with 58% of participants indicating they would allow their genetic data to be banked for research purposes, though there are differing levels of support for genetic data banks across the EU.
  • Trust in actors involved in biotechnology , which shows growing levels of trust in university and industry scientists (73% and 64%). The EU is seen as more trustworthy than national governments on issues of regulating biotechnology (74% compared with 68%).
  • Comparison of attitudes with US and Canada , dispelling claims that European public opinion is more technology-adverse than its transatlantic partners. Close analysis of the data shows that it is inaccurate to ascribe certain attitudes to biotechnology by age group, or gender.

This survey is the latest in a series of such Eurobarometers on biotechnology conducted in 1991, 1993, 1996, 1999, 2002 and 2005. The sixth Eurobarometer on Biotechnology 2005 is based on a representative sample of 25 000 respondents, approximately 1 000 in each EU Member State.

The experts who undertook this survey will present the findings at a workshop on 22 June. To download the full report and read the executive summary, please visit: www.ec.europa.eu/research/press/2006/pr1906en.cfm

Most Popular Now

Most Advanced Artificial Touch for Brain…

For the first time ever, a complex sense of touch for individuals living with spinal cord injuries is a step closer to reality. A new study published in Science, paves...

Predicting the Progression of Autoimmune…

Autoimmune diseases, where the immune system mistakenly attacks the body's own healthy cells and tissues, often have a preclinical stage before diagnosis that’s characterized by mild symptoms or certain antibodies...

Major EU Project to Investigate Societal…

A new €3 million EU research project led by University College Dublin (UCD) Centre for Digital Policy will explore the benefits and risks of Artificial Intelligence (AI) from a societal...

Using AI to Uncover Hospital Patients�…

Across the United States, no hospital is the same. Equipment, staffing, technical capabilities, and patient populations can all differ. So, while the profiles developed for people with common conditions may...

New AI Tool Uses Routine Blood Tests to …

Doctors around the world may soon have access to a new tool that could better predict whether individual cancer patients will benefit from immune checkpoint inhibitors - a type of...

New Method Tracks the 'Learning Cur…

Introducing Annotatability - a powerful new framework to address a major challenge in biological research by examining how artificial neural networks learn to label genomic data. Genomic datasets often contain...

Picking the Right Doctor? AI could Help

Years ago, as she sat in waiting rooms, Maytal Saar-Tsechansky began to wonder how people chose a good doctor when they had no way of knowing a doctor's track record...

From Text to Structured Information Secu…

Artificial intelligence (AI) and above all large language models (LLMs), which also form the basis for ChatGPT, are increasingly in demand in hospitals. However, patient data must always be protected...

AI Innovation Unlocks Non-Surgical Way t…

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients’ cancer without aggressive surgery. The proof-of-concept study, co-led...

Deep Learning Model Helps Detect Lung Tu…

A new deep learning model shows promise in detecting and segmenting lung tumors, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA)...

One of the Largest Global Surveys of Soc…

As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch...

New Study Reveals AI's Transformati…

Intensive care units (ICUs) face mounting pressure to effectively manage resources while delivering optimal patient care. Groundbreaking research published in the INFORMS journal Information Systems Research highlights how a novel...